A FLEXIBLE SENSITIVITY ANALYSIS APPROACH FOR UNMEASURED CONFOUNDING WITH MULTIPLE TREATMENTS AND A BINARY OUTCOME WITH APPLICATION TO SEER-MEDICARE LUNG CANCER DATA

被引:0
|
作者
Hu, Liangyuan [1 ]
Zou, Jungang [2 ]
Gu, Chenyang [3 ]
Ji, Jiayi [4 ]
Lopez, Michael [5 ]
Kale, Minal [6 ]
机构
[1] Rutgers State Univ, Dept Biostat & Epidemiol, New Brunswick, NJ 08854 USA
[2] Columbia Univ, Dept Biostat, New York, NY 10027 USA
[3] Brown Univ, Dept Biostat, Providence, RI 02912 USA
[4] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA
[5] Skidmore Coll, Dept Math, Saratoga Springs, NY 12866 USA
[6] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
来源
ANNALS OF APPLIED STATISTICS | 2022年 / 16卷 / 02期
关键词
Causal inference; ignorability assumption; observational data; Bayesian inference; nested multiple imputation; IMPUTATION; MODEL;
D O I
10.1214/21-AOAS1530
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
In the absence of a randomized experiment, a key assumption for drawing causal inference about treatment effects is the ignorable treatment assignment. Violations of the ignorability assumption may lead to biased treatment effect estimates. Sensitivity analysis helps gauge how causal conclusions will be altered in response to the potential magnitude of departure from the ignorability assumption. However, sensitivity analysis approaches for unmeasured confounding in the context of multiple treatments and binary outcomes are scarce. We propose a flexible Monte Carlo sensitivity analysis approach for causal inference in such settings. We first derive the general form of the bias introduced by unmeasured confounding, with emphasis on theoretical properties uniquely relevant to multiple treatments. We then propose methods to encode the impact of unmeasured confounding on potential outcomes and adjust the estimates of causal effects in which the presumed unmeasured confounding is removed. Our proposed methods embed nested multiple imputation within the Bayesian framework, which allow for seamless integration of the uncertainty about the values of the sensitivity parameters and the sampling variability as well as use of the Bayesian Additive Regression Trees for modeling flexibility. Expansive simulations validate our methods and gain insight into sensitivity analysis with multiple treatments. We use the SEER-Medicare data to demonstrate sensitivity analysis using three treatments for early stage nonsmall cell lung cancer. The methods developed in this work are readily available in the R package SAMTx.
引用
收藏
页码:1014 / 1037
页数:24
相关论文
共 50 条
  • [1] Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data
    Wieder, Robert
    Adam, Nabil
    [J]. CANCERS, 2023, 15 (17)
  • [2] Opportunities for personalizing colorectal cancer care: an analysis of SEER-medicare data
    Zachary T. Rivers
    Helen M. Parsons
    Pamala A. Jacobson
    Karen M. Kuntz
    Joel F. Farley
    David J. Stenehjem
    [J]. The Pharmacogenomics Journal, 2022, 22 : 198 - 209
  • [3] Opportunities for personalizing colorectal cancer care: an analysis of SEER-medicare data
    Rivers, Zachary T.
    Parsons, Helen M.
    Jacobson, Pamala A.
    Kuntz, Karen M.
    Farley, Joel F.
    Stenehjem, David J.
    [J]. PHARMACOGENOMICS JOURNAL, 2022, 22 (03): : 198 - 209
  • [4] Evaluation of the Completeness of Managed Care Data to Identify Cancer Diagnoses and Treatments for Patients in the SEER-Medicare Data
    Warren, Joan L.
    Parsons, Helen M.
    Mariotto, Angela B.
    Boyd, Eric
    Enewold, Lindsey
    [J]. MEDICAL CARE, 2023, 61 (12) : 846 - 857
  • [5] Treatment of localized prostate cancer: A survival analysis using seer-Medicare data
    Wong, YN
    Wan, F
    Mitra, N
    Localio, R
    Montagnet, C
    Hudes, G
    Armstrong, K
    [J]. JOURNAL OF UROLOGY, 2006, 175 (04): : 212 - 212
  • [6] FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data
    Neugut, Alfred I.
    Lin, Aijing
    Raab, Gabriel T.
    Hillyer, Grace Clarke
    Keller, Deborah
    O'Neil, Daniel S.
    Accordino, Melissa Kate
    Kiran, Ravi P.
    Wright, Jason
    Hershman, Dawn L.
    [J]. CLINICAL COLORECTAL CANCER, 2019, 18 (02) : 133 - 140
  • [7] One year mortality following pancreatectomy for pancreatic cancer: analysis of the SEER-Medicare data
    Nayar, Preethy
    Are, Chandrakanth
    Yu, Fang
    Chandak, Aastha N.
    Gupta, Niodita
    [J]. CANCER RESEARCH, 2015, 75
  • [8] Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study
    Shao, Changxia
    He, Jinghua
    Kachroo, Sumesh
    Jin, Fan
    [J]. CANCER MEDICINE, 2019, 8 (18): : 7613 - 7622
  • [9] Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis
    Kim, Sungjin
    Ragin, Camille
    Chen, Zhengjia
    Behera, Madhusmita
    Pillai, Rathi
    Steuer, Conor
    Belani, Chandra
    Khuri, Fadlo
    Ramalingam, Suresh
    Owonikoko, Taofeek
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S703 - S704
  • [10] Impact Of HIV Infection On Survival In Lung Cancer Patients In The Era Of HAART: A SEER-Medicare Analysis
    Rengan, R.
    Mitra, N.
    Liao, K.
    Armstrong, K.
    Vachani, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S276 - S277